EUVIMEDEUVIMED entdecken
Zurückgezogene PublikationOpen Access · CC BY 4.0

Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation

Md Mijanur Rahman, Md Habib Ullah Masum, Rehana Parvin, Shuvo Chandra Das, Asma Talukder iD

PLOS ONE · 06.01.2025 · 20 (1) · e0313559

DOI: 10.1371/journal.pone.0313559 ↗

Kurz gefasst

Zurückgezogene Publikation in der Zeitschrift PLOS ONE, online erschienen am 06.01.2025. Verfasst von Md Mijanur Rahman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Papillomavirus E7 Proteins, mRNA Vaccines, Papillomavirus Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus 16 and human papillomavirus 18 have been associated with different life-threatening cancers, including cervical, lung, penal, vulval, vaginal, anal, and oropharyngeal cancers, while cervical cancer is the most prominent one. Several research studies have suggested that the oncoproteins E6 and E7 are the leading cause of cancers associated with the human papillomavirus infection. Therefore, we developed two mRNA vaccines (V1 and V2) targeting these oncoproteins. We used several bioinformatics tools to predict helper T lymphocyte, cytotoxic T lymphocyte, and B-cell epitopes derived from the proteins and assessed their antigenicity, allergenicity, and toxicity. Both vaccines were constructed using selected epitopes, linkers, and adjuvants. After that, the vaccines were applied for physicochemical properties, secondary and tertiary structure predictions, and subsequent docking and simulation analyses. Accordingly, vaccine 1 (V1) and vaccine 2 (V2) showed better hydrophilicity with the grand average hydropathicity score of -0.811 and -0.648, respectively. The secondary and tertiary structures of the vaccines were also deemed satisfactory, with high stability indicated by the Ramachandran plot (V1:94.5% and V2:87.1%) and Z scores (V1: -5.15 and V2: -4.1). Docking analysis revealed substantial affinity of the vaccines towards the toll-like receptor-2 (V1: -1159.3, V2: -1246.3) and toll-like receptor-4 (V1: -1109.3, V2: -1244.8) receptors. Molecular dynamic simulation validated structural integrity and indicated varying stability throughout the simulation. Codon optimization showed significant expression of the vaccines (V1:51.88% and V2:51.63%) in E . coli vectors. Furthermore, regarding immune stimulation, the vaccines elicited significant B-cell and T-cell responses, including sustained adaptive and innate immune responses. Finally, thermodynamic predictions indicated stable mRNA structures of the vaccines (V1: -502.60 kcal/mol and V2: -450.90 kcal/mol). The proposed vaccines designed effectively targeting human papillomavirus oncoproteins have demonstrated promising results via robust immune responses, suggesting their suitability for further clinical advancement, including in vitro and in vivo experiments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncogene Proteins, ViralPapillomavirus E7 ProteinsmRNA VaccinesPapillomavirus VaccinesHumansPapillomavirus InfectionsComputational BiologyRepressor ProteinsMolecular Dynamics SimulationMolecular Docking SimulationHuman papillomavirus 16FemaleHuman papillomavirus 18Vaccines, SyntheticEpitopes, T-LymphocyteEpitopes, B-LymphocyteHuman Papillomavirus VirusesImmunoinformaticsDNA-Binding Proteins

Substanzen

Oncogene Proteins, ViralPapillomavirus E7 ProteinsmRNA VaccinesE6 protein, Human papillomavirus type 16Papillomavirus VaccinesRepressor Proteinsoncogene protein E7, Human papillomavirus type 16E6 protein, Human papillomavirus type 18E7 protein, Human papillomavirus type 18Vaccines, Synthetic

Autor:innen und Institutionen

  • Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • Microbiology, Cancer and Bioinformatics Research Group, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • School of Pharmacy and Medical Sciences, Griffith University, Queensland, Australia.
  • Department of Genomics and Bioinformatics, Faculty of Biotechnology and Genetic Engineering, Chattogram Veterinary and Animal Sciences University, Khulshi, Chittagong, Bangladesh.
  • Department of Pathology and Parasitology, Faculty of Veterinary Medicine, Chattogram Veterinary and Animal Sciences University, Khulshi, Chittagong, Bangladesh.
  • Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.

ORCID-Profile: Asma Talukder

Zitieren

APA

Rahman, M. M., Masum, M. H. U., Parvin, R., Das, S. C., & Talukder, A. (2025). Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation. PLOS ONE, 20(1), e0313559. https://doi.org/10.1371/journal.pone.0313559

Vancouver

Rahman MM, Masum MHU, Parvin R, Das SC, Talukder A. Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation. PLOS ONE. 2025;20(1):e0313559. doi:10.1371/journal.pone.0313559

BibTeX
@article{Rahman2025,
  author = {Rahman, Md Mijanur and Masum, Md Habib Ullah and Parvin, Rehana and Das, Shuvo Chandra and Talukder, Asma},
  title = {Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0313559},
  doi = {10.1371/journal.pone.0313559}
}
Kostenlos starten →